PTEN loss is not a determinant of time to castration-resistance following androgen-deprivation therapy in prostate cancer: a study from Jordan

Androgen deprivation therapy (ADT) remains the principal treatment of advanced prostate cancer. However, most patients eventually experience treatment failure, resulting in castrate-resistant prostate cancer (CRPC). Loss of the tumor suppressor gene phosphatase and tensin homolog (PTEN) has been lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzoubi, Abdallah, Al Bashir, Samir, Smairat, Aya, Alrawashdeh, Ahmad, Haddad, Husam, Kheirallah, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251393/
https://www.ncbi.nlm.nih.gov/pubmed/37305830
http://dx.doi.org/10.25122/jml-2023-0034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251393/
https://www.ncbi.nlm.nih.gov/pubmed/37305830
http://dx.doi.org/10.25122/jml-2023-0034

Ejemplares similares